Eisai Co., Ltd. and Nuvation Bio Inc. have announced the validation of their Marketing Authorisation Application (MAA) for taletrectinib by the European Medicines Agency (EMA). This application is for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC) and will follow a standard review timeline.
Taletrectinib, marketed as IBTROZI in the U.S. and Japan, is a selective, next-generation oral treatment for advanced ROS1+ NSCLC. Eisai and Nuvation Bio entered into an exclusive licensing and collaboration agreement in Europe and other regions outside the U.S., China, and Japan in January 2026 to expand the global reach of taletrectinib.
Following the EMA filing, additional applications are planned for the U.K., Canada, and other regions within Eisai's licensed territories. NSCLC accounts for 80% of lung cancer cases in Europe, with approximately 2% of these being ROS1+.
The MAA is based on data from two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, which evaluated taletrectinib globally. Results from a pooled analysis were published in the Journal of Clinical Oncology in April 2025, with further data updates anticipated.
Taletrectinib has previously gained full approval from the U.S. FDA for treating locally advanced or metastatic ROS1+ NSCLC, following a Priority Review and Breakthrough Therapy designations. It is also approved in Japan and China, marketed under different brand names.
David Hung, CEO of Nuvation Bio, expressed enthusiasm for the EMA's acceptance of the MAA, marking a significant milestone in the global development strategy for taletrectinib. The goal is to deliver this therapy to more patients in Europe and worldwide.
With over one million global diagnoses of NSCLC annually, the need for effective treatments like taletrectinib is critical, particularly for ROS1+ cases that often progress to the brain, a common site for disease advancement.
As Eisai and Nuvation Bio await the EMA's decision, expected in the first half of 2027, they continue to prepare for further regulatory submissions to expand taletrectinib's availability to patients in need of targeted cancer therapies.